ALKERMES | ALKS - Ebitda





Ebitda Veränderung Datum
AbbVie USD 3.69B 1.68B 2026-03
Acadia Pharmaceuticals USD -1.62M 21.94M 2026-03
ALKERMES USD 139.22M 58.96M 2026-06
Amgen USD 3.86B 1.28B 2026-03
Biogen USD 649.7M 76.5M 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Bristol-Myers Squibb USD 4.24B 1.37B 2026-03
Coherus Biosciences USD -43.33M 4.7M 2025-09
Eli Lilly USD 12.14B 4.26B 2025-12
Gilead Sciences USD 3.51B 489M 2026-03
Heron Therapeutics USD -3.88M 5.63M 2024-09
Ionis Pharmaceuticals USD -64.53M 135.49M 2026-03
J&J USD 8.27B 1.08B 2026-03
Malin Corporation EUR -1.1M 200K 2024-12
Merck USD -1.54B 7.84B 2026-03
Minerva Neurosciences USD -4.36M 1.71M 2024-09
Nektar Therapeutics USD -38.9M 7.09M 2026-03
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Otsuka Holdings JPY 156.66B 56.89B 2026-03
Pfizer USD 6.01B 18M 2026-06
Regeneron Pharmaceuticals USD 1.66B 695.2M 2026-06
Vertex Pharmaceuticals USD 1.19B 195.3M 2026-03